Literature DB >> 6411375

Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

E Garattini, T Colombo, M G Donelli, P Catalani, M Bianchi, M D'Incalci, C Pantarotto.   

Abstract

The covalent binding of hexamethylmelamine (HMM) and its metabolites was studied in liver, tumor, blood, kidney, spleen, lung, brain, heart, and small intestine after a single IP injection of 2,4,6-14C-hexamethylmelamine (50 mg/kg) to C57Bl/6J female mice bearing 20-day-old M5076/73A ovarian cancer. Covalent binding to tissue macromolecules was measured 2, 10, and 40 h after injection of the drug. At 2 h liver and small intestine showed the highest levels of irreversibly bound metabolites, the lowest being found in brain and heart. Except in the small intestine, where a decrease was observed between 2 and 10 h, the level of covalent binding was constant up to 40 h. HMM metabolism was also studied. Tissue distribution of pentamethylmelamine (PMM), 2,2,4,6-tetramethylmelamine (TMM), and 2,4,6-trimethylmelamine (TriMM) was determined at the three times considered. At 2 h the drug was already extensively metabolized, TriMM being the major metabolite among those determined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411375     DOI: 10.1007/BF00257418

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  Gas chromatographic determination of hexamethylmelamine in mouse plasma.

Authors:  M D'Incalci; P Morazzoni; C Pantarotto
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

2.  Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.

Authors:  P D Bonomi; J Mladineo; B Morrin; G Wilbanks; R E Slayton
Journal:  Cancer Treat Rep       Date:  1979-01

3.  Metabolism of hexamethylmelamine-ring-14C in rats and man.

Authors:  J F Worzalla; B D Kaiman; B M Johnson; G Ramirez; G T Bryan
Journal:  Cancer Res       Date:  1974-10       Impact factor: 12.701

4.  Prolonged low-dosage administration of hexamethylmelamine (NC 13875).

Authors:  W L Wilson; H F Bisel; D Cole; D Rochlin; G Ramirez; R Madden
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

5.  In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice.

Authors:  E Garattini; M G Donelli; T Colombo; R Paesani; C Pantarotto
Journal:  Biochem Pharmacol       Date:  1981-05-15       Impact factor: 5.858

6.  N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine.

Authors:  A Gescher; M D'Incalci; R Fanelli; P Farina
Journal:  Life Sci       Date:  1980-01-14       Impact factor: 5.037

7.  Variable oral absorption of hexamethylmelamine in man.

Authors:  M D'Incalci; G Bolis; C Mangioni; L Morasca; S Garattini
Journal:  Cancer Treat Rep       Date:  1978-12

8.  Hexamethylmelamine. An evaluation of its role in the therapy of cancer.

Authors:  S S Legha; M Slavik; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

9.  Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.

Authors:  L M Lake; E E Grunden; B M Johnson
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

10.  Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.

Authors:  M Broggini; C Rossi; T Colombo; M D'Incalci
Journal:  Cancer Treat Rep       Date:  1982-01
View more
  4 in total

1.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.

Authors:  S Garattini
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 3.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

4.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.